Tagged with Up

France Pascaline Gervoson, CEO of PiLeJe, a family-owned French nutraceutical company, represents the second generation of leadership following her father’s founding vision in 1992. With 27 years within the organisation and five years as Chief Executive, she oversees a EUR 180 million enterprise specialising in dietary supplements distributed through medical prescription…

France France’s territorial landscape is undergoing a profound shift, and departments are emerging as decisive actors in the response to medical deserts, demographic ageing and the widening gaps in prevention and mental health. In this interview, Philippe Gouet provides a rare, ground-level view of how local authorities are reshaping access to…

Italy Top recent stories from Italian pharma, including Angelini’s EUR 150 million EU collaboration for European health startups, Chiesi’s new deals for enzyme replacement therapies and gene editing, and why Menarini is setting its sights on the US.   European Union teams up with Angelini to funnel €150M to European health…

China This week’s China healthcare highlights from PharmaBoardroom content partner Selesta include Elpiscience filing for a Hong Kong IPO after US$250M in financing, Zhejiang Medicine planning an HKEX spin-off for ADC subsidiary Novocodex, Baoji Pharmaceuticals securing HKEX approval with a valuation over RMB 4.87 billion, and Phrontline Biopharma completing US$60M Pre-A+…

Spain The latest stories from Spain’s booming healthcare and life science industry. Spain still leads Europe for clinical trial numbers, while a recent meeting between Spanish PM Pedro Sánchez and Roche CEO Thomas Schinecker on a new manufacturing agreement speaks to global pharma’s continued focus on the country. In other news,…

China This week’s China healthcare highlights from PharmaBoardroom content partner Selesta include GSK’s $50M partnership with LTZ for myeloid cell engagers, Kind Pharma’s RMB 400M+ Series C for anemia and breast cancer programs, and Phrontline’s $60M funding to advance bispecific ADCs. Clinical breakthroughs feature BeOne’s zanidatamab + tislelizumab combo significantly improving…

China This week’s China healthcare highlights from PharmaBoardroom content partner Selesta showcases strong innovation and global ambitions through major licensing deals, IPO activity, and clinical advancements. Notable transactions include Shimai Pharma’s Hong Kong IPO for its next-gen TCE platform, Mindray Medical’s IPO for global expansion, and transformative deals like Third Arc…

Switzerland Ophthalmology is one of the hottest niches in pharma right now. Investment is flowing in, M&A is up, and a broad cast of actors – from Big Pharma to legacy generics players and biotechs – are looking to get in on a market set to top USD 93.7 billion by…

Switzerland In an uncertain world, Europe – with Switzerland at its heart – is reclaiming its role as an epicentre for testing, scaling, and integrating new medical technologies.   While much of the global narrative around the European life sciences market centres on doom and gloom (access delays for innovative medicines,…

Brazil Rogerio Frabetti, General Manager of Biogen Brazil discusses the organisation’s strategic transformation as it expands beyond its neuroscience heritage into immunology whilst maintaining leadership in rare diseases. He articulates Brazil’s elevation to a top-tier global market, outlines ambitious growth trajectories in Alzheimer’s disease and lupus, and addresses the complexities of…

China This week’s China healthcare highlights from PharmaBoardroom content partner Selesta include Lilly’s US$345M AI-driven BsAb licensing deal with XtalPi, IVACTA’s RMB 100M fundraising for in vivo CAR-T therapies, Vigonvita’s HKD 5.873B IPO with 4,974x oversubscription, and Neurocrine’s US$881M global licensing of TransThera’s NLRP3 inhibitors. Clinical breakthroughs feature HighTide’s positive Phase…

China This week’s China healthcare roundup from PharmaBoardroom content partner Selesta highlights Qyuns Therapeutics’ US$1.07 billion licensing deal with Roche, Healthgen Biotech’s RMB 42 billion STAR Market IPO, and Immunofoco’s Series B+ funding for CAR-T therapies. Clinical updates include Bioheng’s CAR-T success in autoimmune diseases, Qyuns’ Phase III results for Crusekitug…